Cargando…
Novel targeting using nanoparticles: an approach to the development of an effective anti-leishmanial drug-delivery system
The study reported here aimed to develop an optimized nanoparticle delivery system for amphotericin B (AmpB) using a polyelectrolyte complexation technique. For this, two oppositely charged polymers presenting anti-leishmanial activity – chitosan (Cs) and chondroitin sulfate (ChS) – were used: Cs as...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931713/ https://www.ncbi.nlm.nih.gov/pubmed/24627630 http://dx.doi.org/10.2147/IJN.S55678 |
_version_ | 1782304701981655040 |
---|---|
author | Ribeiro, Tatiana G Chávez-Fumagalli, Miguel A Valadares, Diogo G França, Juçara R Rodrigues, Lívia B Duarte, Mariana C Lage, Paula S Andrade, Pedro H R Lage, Daniela P Arruda, Leonardo V Abánades, Daniel R Costa, Lourena E Martins, Vivian T Tavares, Carlos AP Castilho, Rachel O Coelho, Eduardo AF Faraco, André AG |
author_facet | Ribeiro, Tatiana G Chávez-Fumagalli, Miguel A Valadares, Diogo G França, Juçara R Rodrigues, Lívia B Duarte, Mariana C Lage, Paula S Andrade, Pedro H R Lage, Daniela P Arruda, Leonardo V Abánades, Daniel R Costa, Lourena E Martins, Vivian T Tavares, Carlos AP Castilho, Rachel O Coelho, Eduardo AF Faraco, André AG |
author_sort | Ribeiro, Tatiana G |
collection | PubMed |
description | The study reported here aimed to develop an optimized nanoparticle delivery system for amphotericin B (AmpB) using a polyelectrolyte complexation technique. For this, two oppositely charged polymers presenting anti-leishmanial activity – chitosan (Cs) and chondroitin sulfate (ChS) – were used: Cs as a positively charged polymer and ChS as a negatively charged polymer. The chitosan (NQ) nanoparticles, chitosan-chondroitin sulfate (NQC) nanoparticles, and chitosan-chondroitin sulfate-amphotericin B (NQC-AmpB) nanoparticles presented a mean particle size of 79, 104, and 136 nm, respectively; and a polydispersity index of 0.2. The measured zeta potential of the nanoparticles indicated a positive charge in their surface, while scanning and transmission electron microscopy revealed spherical nanoparticles with a smooth surface. Attenuated total reflectance-Fourier transform infrared spectroscopy analysis showed an electrostatic interaction between the polymers, whereas the release profile of AmpB from the NQC-AmpB nanoparticles showed a controlled release. In addition, the Cs; ChS; and NQ, NQC, and NQC-AmpB nanoparticles proved to be effective against promastigotes of Leishmania amazonensis and Leishmania chagasi, with a synergistic effect observed between Cs and ChS. Moreover, the applied NQ, NQC, and NQC-AmpB compounds demonstrated low toxicity in murine macrophages, as well as null hemolytic activity in type O(+) human red blood cells. Pure AmpB demonstrated high toxicity in the macrophages. The results show that cells infected with L. amazonensis and later treated with Cs, ChS, NQ, NQC, NQC-AmpB nanoparticles, or pure AmpB presented with a significant reduction in parasite number in the order of 24%, 31%, 55%, 66%, 90%, and 89%, respectively. The data presented indicate that the engineered NQC-AmpB nanoparticles could potentially be used as an alternative therapy to treat leishmaniasis, mainly due its low toxicity to mammals’ cells. |
format | Online Article Text |
id | pubmed-3931713 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-39317132014-03-13 Novel targeting using nanoparticles: an approach to the development of an effective anti-leishmanial drug-delivery system Ribeiro, Tatiana G Chávez-Fumagalli, Miguel A Valadares, Diogo G França, Juçara R Rodrigues, Lívia B Duarte, Mariana C Lage, Paula S Andrade, Pedro H R Lage, Daniela P Arruda, Leonardo V Abánades, Daniel R Costa, Lourena E Martins, Vivian T Tavares, Carlos AP Castilho, Rachel O Coelho, Eduardo AF Faraco, André AG Int J Nanomedicine Original Research The study reported here aimed to develop an optimized nanoparticle delivery system for amphotericin B (AmpB) using a polyelectrolyte complexation technique. For this, two oppositely charged polymers presenting anti-leishmanial activity – chitosan (Cs) and chondroitin sulfate (ChS) – were used: Cs as a positively charged polymer and ChS as a negatively charged polymer. The chitosan (NQ) nanoparticles, chitosan-chondroitin sulfate (NQC) nanoparticles, and chitosan-chondroitin sulfate-amphotericin B (NQC-AmpB) nanoparticles presented a mean particle size of 79, 104, and 136 nm, respectively; and a polydispersity index of 0.2. The measured zeta potential of the nanoparticles indicated a positive charge in their surface, while scanning and transmission electron microscopy revealed spherical nanoparticles with a smooth surface. Attenuated total reflectance-Fourier transform infrared spectroscopy analysis showed an electrostatic interaction between the polymers, whereas the release profile of AmpB from the NQC-AmpB nanoparticles showed a controlled release. In addition, the Cs; ChS; and NQ, NQC, and NQC-AmpB nanoparticles proved to be effective against promastigotes of Leishmania amazonensis and Leishmania chagasi, with a synergistic effect observed between Cs and ChS. Moreover, the applied NQ, NQC, and NQC-AmpB compounds demonstrated low toxicity in murine macrophages, as well as null hemolytic activity in type O(+) human red blood cells. Pure AmpB demonstrated high toxicity in the macrophages. The results show that cells infected with L. amazonensis and later treated with Cs, ChS, NQ, NQC, NQC-AmpB nanoparticles, or pure AmpB presented with a significant reduction in parasite number in the order of 24%, 31%, 55%, 66%, 90%, and 89%, respectively. The data presented indicate that the engineered NQC-AmpB nanoparticles could potentially be used as an alternative therapy to treat leishmaniasis, mainly due its low toxicity to mammals’ cells. Dove Medical Press 2014-02-14 /pmc/articles/PMC3931713/ /pubmed/24627630 http://dx.doi.org/10.2147/IJN.S55678 Text en © 2014 Ribeiro et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Ribeiro, Tatiana G Chávez-Fumagalli, Miguel A Valadares, Diogo G França, Juçara R Rodrigues, Lívia B Duarte, Mariana C Lage, Paula S Andrade, Pedro H R Lage, Daniela P Arruda, Leonardo V Abánades, Daniel R Costa, Lourena E Martins, Vivian T Tavares, Carlos AP Castilho, Rachel O Coelho, Eduardo AF Faraco, André AG Novel targeting using nanoparticles: an approach to the development of an effective anti-leishmanial drug-delivery system |
title | Novel targeting using nanoparticles: an approach to the development of an effective anti-leishmanial drug-delivery system |
title_full | Novel targeting using nanoparticles: an approach to the development of an effective anti-leishmanial drug-delivery system |
title_fullStr | Novel targeting using nanoparticles: an approach to the development of an effective anti-leishmanial drug-delivery system |
title_full_unstemmed | Novel targeting using nanoparticles: an approach to the development of an effective anti-leishmanial drug-delivery system |
title_short | Novel targeting using nanoparticles: an approach to the development of an effective anti-leishmanial drug-delivery system |
title_sort | novel targeting using nanoparticles: an approach to the development of an effective anti-leishmanial drug-delivery system |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931713/ https://www.ncbi.nlm.nih.gov/pubmed/24627630 http://dx.doi.org/10.2147/IJN.S55678 |
work_keys_str_mv | AT ribeirotatianag noveltargetingusingnanoparticlesanapproachtothedevelopmentofaneffectiveantileishmanialdrugdeliverysystem AT chavezfumagallimiguela noveltargetingusingnanoparticlesanapproachtothedevelopmentofaneffectiveantileishmanialdrugdeliverysystem AT valadaresdiogog noveltargetingusingnanoparticlesanapproachtothedevelopmentofaneffectiveantileishmanialdrugdeliverysystem AT francajucarar noveltargetingusingnanoparticlesanapproachtothedevelopmentofaneffectiveantileishmanialdrugdeliverysystem AT rodriguesliviab noveltargetingusingnanoparticlesanapproachtothedevelopmentofaneffectiveantileishmanialdrugdeliverysystem AT duartemarianac noveltargetingusingnanoparticlesanapproachtothedevelopmentofaneffectiveantileishmanialdrugdeliverysystem AT lagepaulas noveltargetingusingnanoparticlesanapproachtothedevelopmentofaneffectiveantileishmanialdrugdeliverysystem AT andradepedrohr noveltargetingusingnanoparticlesanapproachtothedevelopmentofaneffectiveantileishmanialdrugdeliverysystem AT lagedanielap noveltargetingusingnanoparticlesanapproachtothedevelopmentofaneffectiveantileishmanialdrugdeliverysystem AT arrudaleonardov noveltargetingusingnanoparticlesanapproachtothedevelopmentofaneffectiveantileishmanialdrugdeliverysystem AT abanadesdanielr noveltargetingusingnanoparticlesanapproachtothedevelopmentofaneffectiveantileishmanialdrugdeliverysystem AT costalourenae noveltargetingusingnanoparticlesanapproachtothedevelopmentofaneffectiveantileishmanialdrugdeliverysystem AT martinsviviant noveltargetingusingnanoparticlesanapproachtothedevelopmentofaneffectiveantileishmanialdrugdeliverysystem AT tavarescarlosap noveltargetingusingnanoparticlesanapproachtothedevelopmentofaneffectiveantileishmanialdrugdeliverysystem AT castilhorachelo noveltargetingusingnanoparticlesanapproachtothedevelopmentofaneffectiveantileishmanialdrugdeliverysystem AT coelhoeduardoaf noveltargetingusingnanoparticlesanapproachtothedevelopmentofaneffectiveantileishmanialdrugdeliverysystem AT faracoandreag noveltargetingusingnanoparticlesanapproachtothedevelopmentofaneffectiveantileishmanialdrugdeliverysystem |